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Abstract: The mechanism(s) of volatile anesthetics (VAs) are poorly under-
stood. High-resolution NMR spectroscopy was used to determine the structure 
of the halothane–[Ca2+]4-calmodulin ([Ca2+]4-CaM) complex, and it was found 
that halothane molecules bind in the druggable sites. Then it was examined 
whether  VAs  binding  to  druggable  sites  in  calmodulin  would  affect  the 
[Ca2+]4-CaM  dependent  activity  of  myosin  light  chain  kinase.  Fluorescence 
assays  were  used  to  determine  that  VA  mediate  [Ca2+]4-CaM  activation  of 
smooth-muscle-myosin-light-chain-kinase (smMLCK), but do not alter signi-
ficantly the Kd of [Ca2+]4-CaM binding to skeletal-myosin-light-chain-kinase-
peptide recognition sequence (skMLCKp). The results suggested that VAs do 
not alter [Ca2+]4-CaM dependent MLCK activity via direct interactions with 
[Ca2+]4-CaM.  
Keywords: volatile anesthetic, calmodulin, halothane, drugs, protein structure. 
INTRODUCTION 
Volatile anesthetic (VA) drugs are used extensively with little knowledge of 
their cellular targets or mechanisms. The targets likely include proteins because 
anesthetic  effects  ultimately  manifest  as  changes  in  protein  function.  This  is 
further supported by the observation that the bioluminescent protein luciferase is 
inhibited in vitro by direct interaction with a variety of anesthetic agents.1  
Calmodulin  (CaM)  is  a  ubiquitous  Ca2+  second  messenger  that  regulates 
many anesthetic sensitive systems. CaM has two EF hands, Ca2+-binding domains 
that can bind up to 2 Ca2+ ions each. The EF hands are located at the N- and 
C- termini and are separated by a flexible central helix. The main difference 
between calcium-free CaM (apoCaM) and [Ca2+]4-CaM is the interhelical angle 
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between  the  Ca2+  binding  domains,  which  increases  upon  Ca2+  binding  and 
exposes large hydrophobic pockets in each termini to the aqueous environment.2 
These hydrophobic pockets are critical for the interaction of [Ca2+]4-CaM with 
many proteins and hence the regulation of numerous enzymatic pathways. The 
Ca2+ dissociation constant (Kd) of [Ca2+]4-CaM is decreased by ligands, pep-
tides, and proteins to the extent that they reduce the effective hydrophobic sur-
face of [Ca2+]4-CaM exposed to an aqueous environment.3 In other words, Ca2+ 
signaling through CaM is partially tuned by the target. 
[Ca2+]4-CaM antagonists bind in the hydrophobic pockets of [Ca2+]4-CaM,4 
with a concomitant decrease in the Ca2+ Kd of [Ca2+]4-CaM,5 and inhibition of 
[Ca2+]4-CaM activation of enzyme activity.6 Short chain n-alcohols also bind to 
the hydrophobic pockets of [Ca2+]4-CaM,7 and decrease the Ca2+ Kd of [Ca2+]4- 
-CaM.8  
It was found and verified that the VAs halothane and isoflurane decrease the 
Ca2+ Kd of [Ca2+]4-CaM.9,10 It was shown that VAs bind to [Ca2+]4-CaM, but 
not to apoCaM.10 This suggests that VAs bind to sites in [Ca2+]4-CaM that are 
either not present or not accessible in apoCaM. Together, these finding suggest 
that VAs bind to the hydrophobic pockets of [Ca2+]4-CaM. This was supported 
by docking studies that indicated that the VAs halothane, isoflurane, and sevo-
flurane bind within the hydrophobic pockets in both the N- and C-termini.10,11 
Thus, it was posited that VAs, as alcohols, would inhibit [Ca2+]4-CaM dependent 
enzymes and might directly antagonize [Ca2+]4-CaM. 
The objective of this work was to verify that VAs bind to the hydrophobic 
pockets  in  [Ca2+]4-CaM  and  determine  whether  they  antagonize  the  [Ca2+]4- 
-CaM-dependent myosin light chain kinase (smMLCK) activity. This work is 
significant because it will test whether the effects of VAs on protein function 
could arise from low affinity ligand binding to druggable sites. 
EXPERIMENTAL 
Proteins and peptides 
Human calmodulin cDNA was sub-cloned into the pET-15b expression vector (Novagen, 
San Diego, CA) using standard cloning techniques. CaM was overexpressed in BL21(DE3)-
pLysS strain of Escherichia coli (Single Shot, Novagen, San Diego, CA). Uniform 13C, 15N 
enrichment was achieved by growing cells in Luria–Bertani medium and then inducing in 
minimal media containing  13C-glucose and  15NH4Cl following established protocols.12 Iso-
topically labeled and unlabeled CaM were purified using a slight modification to an existing 
procedure.13 Thus, 5 mM CaCl2 was added to the cleared cell lysate, which was loaded onto a 
phenyl-sepharose CL-4B column (Sigma, St. Louis, MO), and the CaM was eluted with 1 mM 
ethylene glycol tetraacetic acid (EGTA). The CaM fractions were further purified using a 
HiTrap Q column (Amersham Biosciences, Uppsala, Sweden) and a 0–1 M NaCl gradient. 
CaM was greater than 95 % pure, judging by SDS-gel electrophoresis with Coomassie Bril-
liant Blue staining. The identity of the CaM was confirmed by N-terminal sequencing as well 
as by LC–MS analysis of tryptic digests of labeled and unlabeled CaM. The molecular weight 
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and labeling efficiency (96 %) were verified by ESI-MS by direct infusion. Smooth muscle 
myosin light chain kinase (smMLCK) isoform 5 was prepared as previously described.14 
Human  MLC  cDNA  was  sub-cloned  into  pET-15b  expression  vector  (Novagen,  San 
Diego, CA) using standard cloning techniques. MLC was overexpressed in BL21(DE3)-pLysS 
strain of E. coli (Single Shot, Novagen, San Diego, CA). The regulatory light chain (AL050318) 
was amplified from dT-primed cDNA derived from human lens epithelial cells using Fusion 
polymerase  from  New  England  Bio  Labs.  The  primers  used  for  amplification  were Nde1 
forward  gccatatgtccagcaagcgggccaa  and  Spe1  reverse  gaactagtctagtcgtctttatccttggcgcc.  The 
amplified cDNA was cloned into a pET 15 B vector containing an N-terminal his tag linear-
ized with Nde1 and Spe1 using standard cloning techniques. Recombinant clones were sequ-
ence verified. Protein expression was performed using Magic Media (Invitrogen). Briefly, an 
isolated clone was grown overnight in 50 ml Magic Media. The cells were pelleted by centri-
fugation at 5000g and lysed in Bug Buster media (Novagen). The inclusion bodies were col-
lected by centrifugation and resuspended in 50 mM Tris–HCl (pH 8), 7 M urea, 250 mM 
NaCl, and 1 mM 2-mercaptoethanol. The solution was passed over a Ni-NTA column equilib-
rated in the same buffer. The protein was refolded on the column using a urea gradient (8 to 0 
M) flowing at 0.2 ml min-1 for 16 h. The protein was eluted using a buffer containing 50 % 
glycerol, 50 mM Tris–HCl (pH 8), 250 mM imidazole, and 1 mM 2-mercaptoethanol. The 
MLC  was  judged  greater  than  90  %  pure  by  SDS-PAGE  with  Coomassie  Brilliant  Blue 
staining. 
The skeletal myosin light chain kinase peptide recognition sequence (skMLCKp) (biotin-
CAAARWKKNFIAVSAANRFKKIS) was synthesized by Genetech, inc. (San Antonio, TX).  
Lactate dehydrogenase, pyruvate kinase, phosphoenolpyruvate (PEP), NADH, and ATP 
were purchased from Sigma (St. Louis, MO).  
NMR spectroscopy 
Samples of 2mM [13C,15N]CaM, or 2mM [15N]CaM, in aqueous solvent (95 % H2O, 5 % 
D2O), containing 100 mM KCl, 50 mM 3-morpholinopropane-1-sulfonic acid (MOPS, pH 
7.2), 20 mM CaCl2, 5 mM MgCl, 1 mM EDTA, were equilibrated with halothane to various 
mole ratios. It was possible to achieve up to about 1:70 CaM:halothane ratio, as determined by 
proton NMR. For structure determination the samples with 1:10 CaM:halothane ratio were 
used.  Preparation  of  samples  in  the  oriented  media,  for  measurements  of  residual  dipolar 
coupling (RDC), failed because of interference with halothane. It was found that the phage 
media coagulated upon halothane addition, and gel media gave a prohibitory fast relaxation in 
the presence of halothane. NMR experiments were performed at 25 °C on a 700 MHz spec-
trometer (Bruker Avance 700) equipped with a cryo-probe. Backbone and side-chain assign-
ments  were  obtained  using  a  combination  of  standard  triple  resonance  experiments.15  2D 
HNHA, 3D HNCO, HNCA, HN(CO)CA, HNCACB and CBCA(CO)NH were used for the 
1H, 15N and 13C assignments of the protein backbone. Side-chains 1H and 13C assignments of 
the  non-aromatic  side  chains  were  obtained  using  3D  HAHB(CO)NH,  (H)CC(CO)NH, 
HCCH-COSY and HCCH-TOCSY spectra. Assignments were crosschecked for consistency 
with 3D 15N-edited and 13C-edited [1H, 1H]-NOESY spectra. The 1H and 13C spin systems of 
the  aromatic  side-chains  where  identified  using  3D  HCCH-COSY  and  HCCH-TOCSY 
spectra, while the sequential assignment was based on NOE connectivity in the  13C-edited 
[1H, 1H]-NOESY spectrum. Methionine methyl-group 1H and 13C assignment was achieved 
using methionine-methyl 13Cε-filtered [1H–13C]-HSQC spectrum and 13Cγ,ε-filtered [1H–13C]- 
-HMBC spectrum.15 NOESY spectra for structural constraints were recorded at mixing times 
of 50 ms, 100 ms and 150 ms. Quantitative J-correlation HNHA experiment15 was used for 
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measurement of 3J(HNHα) couplings. The 1H–15N heteronuclear NOEs16 were recorded using 
a 500 MHz spectrometer (Bruker Avance 500). The multidimensional spectra were processed 
and  analyzed  in  FELIX  (Felix  NMR,  2007).  All  analyses  performed  after  peak  picking 
(assignments and structural parameter calculations) were realized using custom programs in 
MATLAB (The MathWorks, 2007). About 1600 NOE  distances (including 19 halothane–
protein  distances)  where  extracted  (see  Table  I  in  Results)  and  applied  with  error  limits 
deduced  from  values  obtained  at  three  mixing  times.  The  backbone  NOE  contacts  and 
3J(HNHα) couplings were in agreement with NMR solution structure of [Ca2+]4-CaM (1J7O & 
1J7P17).  Therefore,  backbone  dihedral  angles  of  the  free  [Ca2+]4-CaM  were  used  as 
constraints  with  an  error  limit  of  ±10,  except  in  few  regions  of  missing  experimental 
couplings or a larger chemical shift difference at the backbone between free and complexed 
CaM.  In  these  regions  (residues:  19–21,  38–43,  54–57,  63–67,  70–76,  92– 
–95, 104–108, 144–147) error limits were increased to ±30. All H-bonds of free [Ca2+]4-CaM 
were also enforced by the distance constraints. Additional distance constraints were defined to 
maintain coordination geometry around Ca2+. 
Structure calculations 
The initial conformation of the [Ca2+]4-CaM N-terminus lobe (residues 1–76) or C-ter-
minus  lobe  (82–148)  was  set  to  the  most  representative  conformer  of  the  reported  NMR 
solution  structure  of  [Ca2+]4-CaM,  1J7O.pdb  or  1J7P.pdb,  respectively.17  Halothane  was 
positioned ≈5 Å above the hydrophobic pocket of each terminus. QUANTA/XPLOR18 was 
used for structure calculations: standard simulated annealing schedule, refinement by cooling 
and energy minimization with distance and dihedral restraints. The final structures were not 
sensitive to the initial positioning of halothane. Of the 50 structures produced (for each lobe), 
about 15 were within 10 % of the lowest energy structure. These low-energy structures were 
subjected to a short (100 steps steepest descend) energy minimization in the CHARMm22 
force-field (Molecular Simulations Inc., 1994), without any restraints except that Ca2+ coor-
dination geometry was kept fixed. Five structures (for each lobe) that fully complied with the 
constraints were selected in the final set. 
Data deposition 
The  NMR  constraints  and  atomic  coordinates  for  the  conformers  were  deposited  at 
Protein Data Bank (PDB entries 2kug and 2kuh for N- and C- terminus lobes, respectively). 
[Ca2+]4-CaM-skMLCKp binding 
Binding was determined from the change in emission of the tryptophan residue in the 
skMLCKp peptide measured in a stirred narrow channel 1 cm fluorescence cuvette (Helman) 
using a Fluoromax-3 instrument (Jobin-Yvon-Spex). The excitation wavelength was 280 nm, 
the emission wavelength was 333 nm, the excitation and emission slit widths were 5 nm, and 
the integrated emission intensity was averaged from thirty 1 s scans. The assay buffer was 50 
mM MOPS (pH 7.3), 100 mM KCl, 1 mM MgCl2 and 0.1 mM CaCl2. The solutions were 
filtered and centrifuged to remove light scattering interferants. A set of titration data were 
collected in the following order: the background emission from the buffer was measured first. 
Then 2.7 nM skMLCKp was added into the cuvette and the emission was remeasured. This 
solution was discarded and a fresh volume of buffer was added to a clean cuvette and the 
emission  measured.  Then  [Ca2+]4-CaM  was  added  to  a  concentration  of  1.3  nM  and  the 
emission recorded. Finally, skMLCKp peptide was added to a concentration of 2.7 nM and the 
emission  was  recorded.  The  solution  was  discarded  and  the  series  of  measurements  was 
repeated for 2.7, 4.0, 8.0, and 16.0 nM concentrations of [Ca2+]4-CaM. There was minimal 
_____________________________________________________________________________________________________________________
Copyright (C)2013 SCS
Available online at www.shd.org.rs/JSCS/  HALOTHANE BINDING TO CAM  1659 
variation in the baseline emission intensities between the samples. The  emission intensity 
from the skMLCKp at each [Ca2+]4-CaM concentration was determined by subtracting the 
emission intensity of the sample of [Ca2+]4-CaM and buffer from the corresponding sample of 
[Ca2+]4-CaM,  skMLCKp  and  buffer.  The  skMLCKp  emission  intensity  was  plotted  as  a 
function of [Ca2+]4-CaM concentration with error bars that represent the standard deviation of 
the thirty intensity values collected at 1 s intervals. Three sets of [Ca2+]4-CaM–skMLCKp 
titration data were collected and each was fitted with the following equation:  
     
2
dd
min max
4
2
CaM skMLCK K CaM skMLCK K CaM skMLCK
F F F
skMLCK
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 
 
where Fmin is the emission intensity from 2.7 nM skMLCKp in the absence of [Ca2+]4-CaM, 
Fmax is the emission intensity from 2.7 nM skMLCKp bound to [Ca2+]4-CaM, CaM is the 
concentration of [Ca2+]4-CaM, skMLCKp is the concentration of skMLCKp (fixed at 2.7 nM), 
and Kd is the dissociation constant. 
The  data  fitting  was  realized  using  Origin  7.5  (OriginLab)  and  the  parameters  are 
reported as mean ± sd of the fits to the three-titration data sets.  
[Ca2+]4-CaM-smMLCK activity 
The [Ca2+]4-CaM-dependence of the smMLCK activity was measured using a spectro-
scopic method coupled to pyruvate kinase and lactate dehydrogenase,19 which was modified 
to work in a 96-well format fluorescence plate reader. Briefly, when smMLCK transfers a 
phosphate group from ATP to MLC, it produces a molecule of ADP. Pyruvate kinase (PK) 
acts on ADP and phosphoenolpyruvate (PEP) to produce ATP and pyruvate. Lactate dehyd-
rogenase (LDH) acts on pyruvate and NADH to produce NAD+ and lactate. Thus, for each 
MLC phosphorylated, one molecule of the fluorescent NADH is converted to the non-fluores-
cent NAD+. The specific activity of smMLCK was determined by recording the kinetics of 
NADH disappearance using a Fluostar Optima Fluorescence plate reader (BMG) with 350 and 
460 nm excitation and emission filters, respectively. The kinetic assays were performed in 
triplicate on 200 μl samples. A typical well contained 20 mM MOPS (pH 7.5), 100 mM KCl, 
0.1 mM EGTA, 1.5 mM  dithiothreitol (DTT), 1.2 mM PEP, 10 μM NADH, 4.3 units of 
LDH/PK,  20  μM  regulatory  light  chain  (RLC),  100  ηg  MLCK,  and  various  amounts  of 
[Ca2+]4-CaM. The maximum fluorescence intensity of the NADH in the wells was recorded 
prior to initiating the assay by automatically injecting 10 μl of a solution containing 6 mM 
ATP, 40 mM MgCl2, and 10 mM CaCl2, which dilute to a final concentration of 0.3 mM ATP, 
2  mM  MgCl2,  and  0.5  mM  CaCl2  in  the  wells.  The  time  dependent  decrease  in  NADH 
fluorescence was recorded at 30 s intervals for approximately 10 min, after which the reaction 
was stopped by automatically injecting 10 l of 400 M ADP (20 M final concentration) 
into each well. The baseline fluorescence intensity of the NADH-depleted samples was then 
recorded. 
RESULTS 
Solution structure of [Ca2+]4-CaM–halothane complex 
The aim was to determine the structure of the [Ca2+]4-CaM–halothane com-
plex at low halothane concentrations, because physiological concentrations of a 
VA in anesthesia are rather low. The titration with halothane was followed by 
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NMR (Supplementary material to this paper) and saturation of the [Ca2+]4-CaM 
chemical shifts was established at about 1:30 CaM:halothane mole ratio. Signi-
ficant changes were observed already at a 1:10 mole ratio, which was eventually 
selected  as  concentration  at  which  the  physiologically  relevant  CaM/halothane 
complex might be discernible.  
Chemical shifts of the protein backbone in [Ca2+]4-CaM–halothane complex 
(at  1:10  mole  ratio)  differ  in  several  regions  from  those  of  [Ca2+]4-CaM, 
measured in the absence of halothane (Fig. 1, bottom). The most pronounced dif-
ferences were in the N-terminus. There were no significant differences in the region 
of the central linker (residues 77–82). The regional mobility of the complex, as 
probed by backbone {1H-15N}-NOE (Fig. 1, top), indicates that the central linker 
was mobile when halothane was bound. These findings signify that low-halo-
thane complex of [Ca2+]4-CaM probably retains a flexible and distant disposition 
of the two Ca2+ binding domains, as was found in the NMR solution structure of 
[Ca2+]4-CaM.17 
 
Fig. 1. Top: sequential values (open circles) of the backbone {1H-15N}-NOE; error bars are 
shown only when larger than the size of the open circles. Bottom: comparison of the CaM 
backbone chemical shift difference (Δ1H = |δ1Hcomplex–δ1Hfree|, Δ15N = |δ15Ncomplex–δ15Nfree|) 
between [Ca2+]4-CaM alone (free) and complexed with halothane. 
A number of inter-molecular, [Ca2+]4-CaM to halothane NOE contacts were 
observed in each Ca2+ binding domain. All of them were between the single 
halothane proton and methyl-groups of CaM residues: Leu-32, Val-35, Met-36, 
Leu-39, Met-51, Val-55, Met-71, Met-72 and Met-76 in the N-terminus lobe, and 
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Leu-105, Val-108, Met-109, Leu-112, Met-124, Ala-128, Met-144 and Met-145 
in the C-terminus lobe. The best quality NOE contacts were seen for the methyl 
groups of methionines because of their favorable relaxation properties (Fig. 2). 
Numerous intra-calmodulin NOE contacts (≈800 per lobe) were all in support of 
the lobe structures as found in the NMR solution structure of [Ca2+]4-CaM.17 
 
Fig. 2. Methyl-methionine 13C-filtered 3D NOESY (200 ms mixing time) spectrum of 
[Ca2+]4-CaM–halothane complex. A) Diagonal peaks region (1H region 1.5–2.1 ppm) of the 
spectrum. Peaks are labeled by sequential numbers of the methionines. The corresponding 
positions in halothane free [Ca2+]4-CaM20 are marked by crosses. B) Halothane cross-peaks 
region (1H region: 6.2–6.4 ppm) of the spectrum displayed peaks having centers at 6.3 ppm. 
Calculated methyl–halothane distances are shown. 
The structure of the complex was solved under the assumption that halothane 
binding  has  a  minor  effect  on  the  protein  fold,  which  was  justified  by  the 
similarity of the chemical shifts in [Ca2+]4-CaM determined with and without 
halothane, by the NOE contacts, and the 3J(HNHα) couplings. Thus, the protein 
dihedral angles (ψ, φ and χ1) were constrained to those of free [Ca2+]4-CaM 
except in the regions of more pronounced (> 0.5 ppm) chemical shift differences 
(Fig. 1, bottom). Due to the flexible disposition of the two CaM lobes, the NMR 
solution structure was solved separately for the N-terminus and for the C-ter-
minus lobes. The final structures were similar to the uncomplexed [Ca2+]4-CaM 
_____________________________________________________________________________________________________________________
Copyright (C)2013 SCS
Available online at www.shd.org.rs/JSCS/1662  JURANIĆ et al. 
structure17 having an average deviation between the backbone or side-chains of 
≈2 Å and ≈3 Å, respectively. The structural statistics are given in Table I. 
The obtained structures (Fig. 3) show halothane binding in the region of the 
hydrophobic pockets, which are binding targets for many other ligands.21 The 
N-terminus lobe structural models show a deeper imbedding of halothane than in 
the C-terminus, as could have been expected from the induced chemical shift 
changes of CaM (see above, Fig. 1, bottom). The orientation of the halothane 
varies considerably in the models, because there are no empirical constraints on 
the trifluoromethyl half of the molecule. An attempt was made to obtain addi-
tional constraints by measuring the 1H–19F dipolar couplings in oriented media, 
but halothane was found to disrupt the properties of the orientation media, i.e., 
phage and co-solvents. 
TABLE I. Summary of conformational restraints and structural statistics for 5 energy-refined 
conformers of [Ca2+]4-CaM in complex with halothane 
 Parameter  N-terminus  C-terminus 
NOE distance restraints 
 Intraresidual (|i–j| = 0)  314  337 
 Sequential (|i–j| = 1)  157  188 
 Medium range (1 <|i–j| <5)  131  137 
 Long range (|i–j| 5)  128+9a  137+10a 
 Total NOE  735  808 
Dihedral angle restraintsb (1)  220  195 
H-bond restraintsb  37  23 
RMSD over all distance constraint violations, Å  0.1  0.1 
RMSD over all dihedral angle restraints violations, deg.  2.5  3.2 
CHARMm energiesc, kcal mol-1) 
 Total  –2270±90  –1913±90 
 van der Waals  –316±9  –230±10 
 Electrostatic  –2285±90  –1970±100 
Ramachandran plot statistics, % 
 Residues in most favored region  90.3  95.7 
 Residues in additionally allowed regions  9.7  4.3 
 Residues in generously allowed regions  0  0 
 Residues in disallowed regions  0  0 
Average RMSD from mean coordinates, Å 
 All atoms  0.75  0.64 
aProtein-halothane NOE; 
btarget values are same as in [Ca
2+]4-CaM structure (1J70 & 1P7O); 
ccharged protein 
without Ca
2+ counter-ions contribution 
skMLCKp [Ca2+]4-CaM binding 
The emission spectrum of the skMLCKp peptide excited at 280 nm  was 
measured and it was found that the peak increased in intensity and was blue-
shifted upon binding to [Ca2+]4-CaM (Fig. 4, top panel). This result is consistent 
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with  previous.22  The  most  significant  difference  between  the  spectra  of  the 
bound and unbound peptide was observed at 333 nm. The emission of the peptide 
at 333 nm at various [Ca2+]4-CaM concentrations up to 16 nM was measured 
(Fig. 4, bottom panel). The binding curves yielded a mean Kd of 1.3±0.4 nM, 
which agrees with the Kd value of 4 nM determined previously using surface 
plasmon resonance.23 Moreover, 10 mM isoflurane did not significantly affect 
the fluorescence intensity of skMLCKp in the presence of 2.7 nM [Ca2+]4-CaM. 
 
Fig. 3. Models of five conformers for N-terminus (to the left, 2KUG.pdb) and C-terminus (to 
the right, 2KUH.pdb) lobes of the [Ca2+]4-CaM–halothane complex. Halothane is given in 
cyan color, protein in magenda. The atomic stick-plot is overlain with protein cartoon 
(helices are denoted by letters). 
smMLCK activity 
The specific  activity of smMLCK was determined using an ADP/NADH 
coupled assay. Representative spectra recorded in the presence of various con-
centrations of [Ca2+]4-CaM up to 300 nM illustrate the assay (Fig. 5, top panel). 
The initial plateau is the maximal emission from NADH, determined prior to 
initiating the assay. The drop in intensity (≈10 %) that occurred when a solution 
of ATP, MgCl2, and CaCl2 was automatically injected to start the reaction was 
due to minor ADP contamination. This was followed by a steady decrease in 
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NADH fluorescence that was dependent on the [Ca2+]4-CaM concentration. The 
rate of fluorescence decrease was directly proportional to the phosphorylation of 
the myosin light chain. The final steep drop occurred when an ADP solution was 
automatically injected, which consumes the remaining NADH. The end plateau 
was  the  signal  from  the  sample  without  NADH.  The  difference  between  the 
plateaus at the beginning and end of the assay was used to calibrate the instru-
ment response to the amount of NADH present. 
 
Fig.  4.  Top:  Change  in  tryptophan 
emission  spectrum  (at  280  nm)  from 
skMLCKp  upon  binding  to  [Ca2+]4- 
-CaM. Bottom [Ca2+]4-CaM concentra-
tion  dependence  of  tryptophan  emis-
sion (at 333 nm) from 2.7 nM skMLCKp. 
The  titrations  were  repeated  in  trip-
licate  (circles,  squares  and  triangles). 
The  error  bars  represent  the  standard 
deviation  in  the  mean  of  thirty,  1  s 
fluorescence  measurements. The  solid 
line  was  generated  using  the  mean 
parameters  from  the  curve  fits  to  the 
three sets of titration data. It was found 
that  10  mM  isoflurane  did  not  signi-
ficantly  affect  the  fluorescence  inten-
sity  of  skMLCKp  in  the  presence  of 
2.7 nM [Ca2+]4-CaM (closed stars). 
The specific activities of the smMLCK, calculated from the slopes are plot-
ted as a function of [Ca2+]4-CaM concentration in Fig. 5, bottom panel. The maxi-
mum activity of smMLCK in the presence of [Ca2+]4-CaM was found to be appro-
ximately 12 μmol min–1 mg MLCK–1, which is consistent with previous results.19 
The effect of various concentrations of halothane on the activity of MLCK alone 
and in the presence of [Ca2+]4-CaM at concentrations that produce half-maximal 
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(2 nM) and maximal (100 nM) activation was measured. Halothane was found to 
inhibit the MLCK activity, but it was not [Ca2+]4-CaM dependent (Fig. 6). 
 
Fig. 5. Top: raw fluorescence data 
for assay of CaM-dependent MLCK 
activity. From top to bottom trace, 
CaM concentration was 0, 1, 3, 10, 
30, and 100 nM. Bottom: [Ca2+]4- 
-CaM  dependence  of  MLCK 
specific activity. 
 
Fig. 6. Effect of halothane on MLCK acti-
vity.  The  activities  were  measured  in  the 
presence of 0, 2 and 100 nM concentrations 
of  [Ca2+]4-CaM,  indicated  by  the  triangle, 
circle and square symbols, respectively. The 
activities are normalized to the specific acti-
vity of MLCK measured in the presence of 
100  nM  [Ca2+]4-CaM  without  halothane. 
Increasing concentrations of halothane inhi-
bited  MLCK,  independent  of  the  [Ca2+]4- 
-CaM concentration. 
_____________________________________________________________________________________________________________________
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DISCUSSION 
Halothane binding site 
The NMR solution structure of the [Ca2+]4-CaM–halothane complex appears 
to retain an open structure with a flexible central-linker, which is consistent with 
free [Ca2+]4-CaM. Therefore, halothane binding does not seem to induce a global 
conformational change in the [Ca2+]4-CaM structure. To gain insight into the 
structural features of halothane binding, its binding is compared in Fig. 7 with 
that  of  a  potent  CaM-peptide  binding  antagonist  N-(6-aminohexyl)-5-chloro-1-
naphthalenesulfonamide (W-7).24 Halothane does not penetrate as deep into the 
hydrophobic pockets in the termini of [Ca2+]4-CaM as does W-7. Halothane mainly 
 
Fig. 7. Top: partial structure of the binding sites of N-(6-aminohexyl)-5-chloro-1-naph-
thalenesulfonamide (W-7) to [Ca2+]4-CaM (taken from 1mux.pdb, first NMR structure). 
Shown are the side-chain groups of [Ca2+]4-CaM binding sites in contact with the W-7 
aromatic ring. Bottom: analogous view of the binding site in the [Ca2+]4-CaM–halothane 
structure. The structure of the conformer with a deepest imbedding of halothane is shown. 
Atoms are represented by solid spheres at 50 % of the van der Walls radii. Colors are by atom 
nature: H (white-gray), C (light green), N (blue), O (red), F (deep-green), 
S (yellow), Cl (deep-green), Br (magenta). 
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interacts with methyl groups, primarily from methionine residues, whereas W-7 
also interacts with complementary aromatic groups at the base of the pockets. 
This preferential interaction with methyl groups is likely supported by their high 
concentration at the pockets entry. In a more dominant aromatic environment, 
halothane could also engage aromatic groups.25 The lack of halothane penetra-
tion into the C-terminal pocket is particularly significant because that is where the 
tryptophan side chains (i.e., Trp-4 of the CaM-binding peptide from the MLCK,24 
or Trp-8 of the CaM-binding peptide26,27) anchor the peptide to [Ca2+]4-CaM. 
To  substantiate  further  this  finding,  comparison  of  the  ligand  penetration 
depth  into  the  hydrophobic  pockets  of  [Ca2+]4-CaM  by  triangulation  to  three 
residues at the bottom of the pockets that are iso-topical in the N- and C-termi-
nuses was made (Scheme 1 and Table II). The data in the last two columns of 
Table II verify that ligand penetration depth into the C-terminus hydrophobic 
pocket is crucial for the onset of antagonist behavior. 
 
Scheme 1. Ligand penetration into the hydrophobic 
pockets of [Ca2+]4-CaM. 
TABLE  II.  Ligand  penetration-depths  into  hydrophobic  pockets  of  Ligand/CaM  (Li-
gand/#pdb)  structures  obtained  by  triangulation  to  three  residues  at  the  bottom  of  the 
hydrophobic pockets. Distances (Å ) were calculated between the backbone Cα atom of the 
three residues and the closest heavy atom of the ligand; TFP: 10-[3-(4-methyl-piperazin-1-yl)- 
-propyl]-2-trifluoromethyl-10H-phenothiazine 
Ligand/#pdb  Phe19  Leu32  Phe68  Mean  Phe92  Leu105  Phe141  Mean  Antagonist 
EtOH  C1:  C1:  C2:  –  Any  Any  Any  –  – 
/1cll  8.1  7.5  5.9  5.6  >15  >15  >15  >15  No 
Halothane  Br:  Cl2:  Br:  –  C1:  Cl2:  F2:  –  – 
/2kug, 2kuh  11.5  8.2  7.6  9.1  13.1  7.3  8.3  9.6  No 
W-7  C3:  C4:  C3:  –  C3:  C3:  Cl1:  –  – 
/1mxu  6.4  6.6  7.2  6.7  6.1  6.4  6.4  6.3  Yes 
TFP  C3:  C3:  C2:  –  C9:  C9:  C10:  –  – 
/1ctr  13.6  17.3  15.2  15.4  7.6  5.8  6.5  6.6  Yes 
MLCK  10CB:  14CD1:  17CD2:  –  8O1:  8O1:  4CZ2:  –  – 
/1qs7  7.0  6.9  7.4  7.1  5.3  5.7  5.5  5.5  Yes 
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The finding that halothane interacts with methyl groups in [Ca2+]4-CaM is 
consistent  with  previous  observations  that  VAs  contact  primarily  aliphatic 
residues in serum albumin28 and interact solely with the choline methyl groups in 
dipalmitoylphosphatidylcholine vesicles.29 This appears to be a general feature 
of VAs–protein interactions, which were used as criteria to identify amphiphilic 
pockets in protein structures where VAs bind.10,11 This finding is consistent with 
the possibility that protein methyl groups act as weak hydrogen bond donors to 
the methyl halogens, namely fluorine, found in VAs.30 However, this is only 
speculation because data necessary for the determination of the orientation of 
halothane relative to the methyl groups of [Ca2+]4-CaM is lacking. 
Isoflurane does not affect steady-state [Ca2+]4-CaM–skMLCKp binding 
The steady state fluorescence assay indicated that even high concentrations 
of isoflurane and, by extension, probably other VAs, do not significantly alter the 
amount of [Ca2+]4-CaM–skMLCKp formed in the presence of 2.7 nM [Ca2+]4- 
-CaM. Isoflurane was used because it does not quench fluorescence unlike halo-
thane, which would complicate the interpretation of this assay, and skMLCKp 
was employed because its affinity for [Ca2+]4-CaM is not too high to quantify.23 
Thus VAs do not behave like the [Ca2+]4-CaM antagonist W-7, which reduces 
the amount of [Ca2+]4-CaM–MLCK peptide formed without significantly alte-
ring the Kd value.31 This was unexpected since halothane was shown to reduce 
the amount of synaptic PDZ domain-mediated protein interactions with NMDA 
receptor and nNOS without significantly altering the Kd value.32 It is possible 
that VAs behave like the [Ca2+]4-CaM antagonist TFP and alter the on-rate of the 
MLCK peptide, but not the steady state amount of complex formed.31 However, 
a reduction in the on-rate would increase the steady state Kd and right-shift the 
binding curve. This was not the case since isoflurane had no effect on the inten-
sity observed near the half-maximal [Ca2+]4-CaM. These results indicate that VAs 
do not significantly antagonize the interaction of [Ca2+]4-CaM with skMLCKp.  
Halothane inhibits smMLCK activity 
The kinetic fluorescence assay indicated that the MLCK activity is inhibited 
in a concentration-dependent manner by halothane. Fluorescence quenching by 
halothane does not present a problem for this assay because the instrument res-
ponse is calibrated using the NADH fluorescence from each sample condition. It 
was found that MLCK is inhibited by VAs in the absence of [Ca2+]4-CaM and in 
the presence of sub-maximal and maximal concentrations of [Ca2+]4-CaM. This 
indicates that the mechanism by which halothane inhibits MLCK is independent 
of [Ca2+]4-CaM, which is consistent with the finding that isoflurane does not 
inhibit [Ca2+]4-CaM binding to skMLCKp. 
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CONCLUSIONS 
The obtained results indicate that VAs bind to antagonist sites in [Ca2+]4- 
-CaM,  yet  inhibit  MLCK  activity  only  via  unspecified  interactions  with  the 
enzyme. The inability of VAs to act as potent CaM-peptide binding antagonists 
can be traced to the ligand-penetration-depth into the C-terminus hydrophobic 
pockets. The result is significant because it shows, at least in the case of calmo-
dulin-dependent smMLCK activity, that effect of VAs on enzyme function do not 
arise from the low affinity of VA binding to the druggable sites of the protein.  
Since mechanism of general anesthesia remains unsolved,33 structural stu-
dies at an atomic resolution level, such as those presented herein, could help 
understand modalities of anesthetic–biomacromolecule interactions. 
SUPPLEMENTARY MATERIAL 
Two figures presenting halothane/CaM NMR titration data are available electronically at 
http://www.shd.org.rs/JSCS/  or  at:  https://www.researchgate.net/profile/Nenad_Juranic/pub-
lications/?pubType=dataset&ev=prf_pubs_dat 
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И З В О Д  
ХАЛОТАН СЕ ВЕЗУЈЕ ЗА АКТИВНА МЕСТА [Cа2+]4-КАЛМОДУЛИН, АЛИ НЕ ИНХБИРА 
[Cа2+]4-КАЛМОДУЛИН-ЗАВИСНУ АКТИВАЦИЈУ КИНАЗЕ 
NENAD O. JURANIĆ
1, KEITH A. JONES
2, ALAN R. PENHEITER
1, THOMAS J. HOCK
2 и JOHN H. STREIFF
2 
1Mayo College of Medicine at Rochester, U.S.A. и 
2University of Alabama at Birmingham, U.S.A. 
Механизам  деловања  испарљивих  анестетика  је  слабо  познат.  Применом  NMR 
спектроскопије виосоке резолуције ми смо решили структуру комплекса којег испар-
љиви анестетик халотан чини са калцијум-везујућим протеином калмодулином ([Cа2+]4- 
-CаМ). Утврдили смо да се халотан везује за калмодулин на местима која су позната као 
примарна места везивања разних лиганада, и сматрају се примарним циљем за примену 
лекова у системима зависним о сигнализирању калцијума. То је указивало на могућност 
дејства анестетика путем модулације сигнализирања калцијум-кадмодулина. Зато смо 
испитали да ли везивање испарљивих анестетика (VА) утиче на калцијум-кадмодулин 
зависну активност ензима миозин-киназе (myosin light chain kinase, МLCК). Применом 
флуорeсцентне анализе утврдили смо да VА утичу на активацију МLCК, али да не мења 
константу везивања калцијум-калмодулина за моделну регију ензима (skМLCКp). Овај 
резултат сугерише да анестетик (VА) не утиче директно путем сигнализирања калцијум- 
-кадмодулина. 
(Примљено 23. маја 2013) 
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